利伐沙班单用和联合阿司匹林治疗房颤合并稳定型冠心病患者的有效性和安全性  

Effectiveness and safety of rivaroxaban monotherapy and rivaroxaban combined aspirin on AF patients with stable CHD

作　　者：谢芳[1] 张劲林[1] 韩宏伟[1] XIE Fang;ZHANG Jin-lin;HAN Hong-wei(Department of Cardiology,Wuhan Asia Heart Hospital,Wuhan,Hubei,430000,China)

机构地区：[1]武汉亚洲心脏病医院心内科,湖北武汉430000

出　　处：《心血管康复医学杂志》2022年第2期196-198,共3页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:探讨利伐沙班单用和联合阿司匹林抗栓治疗房颤合并稳定型冠心病患者的有效性和安全性。方法:选择非瓣膜性房颤合并稳定型冠心病患者220例,随机分为利伐沙班组(103例,单独使用利伐沙班治疗)和联合治疗组(117例,利伐沙班联合拜阿司匹林治疗),平均随访时间3年。比较两组患者临床终点事件和临床出血事件的差异。结果:利伐沙班组无临床出血事件生存率显著高于联合治疗组(90.3%比81.2%,P=0.049),两组无临床终点事件生存率无显著性差异(P=0.806)。结论:对于房颤伴稳定型冠心病的患者,单用利伐沙班治疗的无临床出血事件生存率显著高于利伐沙班联合阿司匹林治疗。Objective:To explore effectiveness and safety of rivaroxaban monotherapy and rivaroxaban combined aspirin on patients with atrial fibrillation(AF)complicated stable coronary heart disease(CHD).Methods:A total of 220 patients with non-valvular AF complicated stable CHD were randomly divided into rivaroxaban group(n=103,received rivaroxaban monotherapy)and combined treatment group(n=117,received rivaroxaban combined with aspirin),they were followed up for a mean three years.Clinical endpoint events and bleeding events were compared between two groups.Results:Survival rate of no clinical bleeding events in rivaroxaban group was significantly higher than that of combined treatment group(90.3%vs.81.2%,P=0.049).There was no significant difference in survival rate of no clinical endpoint events between two groups,P=0.806.Conclusion:For AF+stable CHD patients,survival rate of no clinical bleeding events of rivaroxaban monotherapy is significantly higher than that of rivaroxalan combined aspirin.

关 键 词：心房颤动 冠心病 利伐沙班 阿司匹林 

分 类 号：R541.1[医药卫生—心血管疾病]